プロテオミクスによるキナーゼ基質同定法およびチロシンホスファターゼ大規模解析法の開発に関する研究

1. Olsen, J. V. et al. Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci. Signal. 3, ra3 (2010).

2. Sharma, K. et al. Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep. 8, 1583– 1594 (2014).

3. Chen, M. J., Dixon, J. E. & Manning, G. Genomics and evolution of protein phosphatases. Sci. Signal. 10, (2017).

4. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002).

5. Vainonen, J. P., Momeny, M. & Westermarck, J. Druggable cancer phosphatases. Sci. Transl. Med. 13, (2021).

6. Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035–1044 (2007).

7. Needham, E. J., Parker, B. L., Burykin, T., James, D. E. & Humphrey, S. J. Illuminating the dark phosphoproteome. Sci. Signal. 12, (2019).

8. Tonks, N. K. Protein tyrosine phosphatases--from housekeeping enzymes to master regulators of signal transduction. FEBS J. 280, 346–378 (2013).

9. Aebersold, R. et al. How many human proteoforms are there? Nat. Chem. Biol. 14, 206–214 (2018).

10. Hornbeck, P. V. et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 43, D512–20 (2015).

11. Humphrey, S. J., Azimifar, S. B. & Mann, M. High-throughput phosphoproteomics reveals in vivo insulin signaling dynamics. Nat. Biotechnol. 33, 990–995 (2015).

12. Bekker-Jensen, D. B. et al. Rapid and site-specific deep phosphoproteome profiling by data-independent acquisition without the need for spectral libraries. Nat. Commun. 11, 787 (2020).

13. Sugiyama, N. Mass Spectrometry-Based Discovery of Kinome Substrates. Mass Spectrom. 9, A0082 (2020).

14. Ochoa, D. et al. The functional landscape of the human phosphoproteome. Nat. Biotechnol. 38, 365–373 (2020).

15. Dinkel, H. et al. Phospho.ELM: a database of phosphorylation sites--update 2011. Nucleic Acids Res. 39, D261–7 (2011).

16. Keshava Prasad, T. S. et al. Human Protein Reference Database--2009 update. Nucleic Acids Res. 37, D767–72 (2009).

17. Knebel, A., Morrice, N. & Cohen, P. A novel method to identify protein kinase substrates: eEF2 kinase is phosphorylated and inhibited by SAPK4/p38delta. EMBO J. 20, 4360–4369 (2001).

18. Ptacek, J. et al. Global analysis of protein phosphorylation in yeast. Nature 438, 679–684 (2005).

19. Wang, C. et al. Determination of CK2 specificity and substrates by proteome- derived peptide libraries. J. Proteome Res. 12, 3813–3821 (2013).

20. Newman, R. H. et al. Construction of human activity-based phosphorylation networks. Mol. Syst. Biol. 9, 655 (2013).

21. Sugiyama, N. & Ishihama, Y. Large-scale profiling of protein kinases for cellular signaling studies by mass spectrometry and other techniques. J. Pharm. Biomed. Anal. 130, 264–272 (2016).

22. Sugiyama, N., Imamura, H. & Ishihama, Y. Large-scale Discovery of Substrates of the Human Kinome. Sci. Rep. 9, 10503 (2019).

23. Imamura, H., Sugiyama, N., Wakabayashi, M. & Ishihama, Y. Large-Scale Identification of Phosphorylation Sites for Profiling Protein Kinase Selectivity. Journal of Proteome Research vol. 13 3410–3419 (2014).

24. Imami, K. et al. Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol. Cell. Proteomics 11, 1741–1757 (2012).

25. Pan, C., Olsen, J. V., Daub, H. & Mann, M. Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol. Cell. Proteomics 8, 2796–2808 (2009).

26. Kim, J.-Y. et al. Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc. Natl. Acad. Sci. U. S. A. 110, 12414–12419 (2013).

27. Chen, Z. et al. Global phosphoproteomic analysis reveals ARMC10 as an AMPK substrate that regulates mitochondrial dynamics. Nat. Commun. 10, 104 (2019).

28. Bodenmiller, B. et al. Phosphoproteomic analysis reveals interconnected system-wide responses to perturbations of kinases and phosphatases in yeast. Sci. Signal. 3, rs4 (2010).

29. Imamura, H. et al. Identifications of Putative PKA Substrates with Quantitative Phosphoproteomics and Primary-Sequence-Based Scoring. J. Proteome Res. 16, 1825–1830 (2017).

30. Xue, L. et al. Sensitive kinase assay linked with phosphoproteomics for identifying direct kinase substrates. Proc. Natl. Acad. Sci. U. S. A. 109, 5615–5620 (2012).

31. Arrington, J., Xue, L., Wang, W.-H., Geahlen, R. L. & Tao, W. A. Identification of the Direct Substrates of the ABL Kinase via Kinase Assay Linked Phosphoproteomics with Multiple Drug Treatments. J. Proteome Res. 18, 1679–1690 (2019).

32. Linding, R. et al. Systematic discovery of in vivo phosphorylation networks. Cell 129, 1415–1426 (2007).

33. Yachie, N., Saito, R., Sugiyama, N., Tomita, M. & Ishihama, Y. Integrative features of the yeast phosphoproteome and protein-protein interaction map. PLoS Comput. Biol. 7, e1001064 (2011).

34. Wagih, O., Sugiyama, N., Ishihama, Y. & Beltrao, P. Uncovering Phosphorylation-Based Specificities through Functional Interaction Networks. Mol. Cell. Proteomics 15, 236–245 (2016).

35. Amano, M. et al. A proteomic approach for comprehensively screening substrates of protein kinases such as Rho-kinase. PLoS One 5, e8704 (2010).

36. Roux, K. J., Kim, D. I., Raida, M. & Burke, B. A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells. J. Cell Biol. 196, 801–810 (2012).

37. Rhee, H.-W. et al. Proteomic mapping of mitochondria in living cells via spatially restricted enzymatic tagging. Science 339, 1328–1331 (2013).

38. Cutler, J. A. et al. Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis. Leukemia 31, 1513–1524 (2017).

39. Liu, X. et al. An AP-MS- and BioID-compatible MAC-tag enables comprehensive mapping of protein interactions and subcellular localizations. Nat. Commun. 9, 1188 (2018).

40. Méant, A. et al. Proteomic Analysis Reveals a Role for RSK in p120-catenin Phosphorylation and Melanoma Cell-Cell Adhesion. Mol. Cell. Proteomics 19, 50–64 (2020).

41. Cox, J. et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell. Proteomics 13, 2513–2526 (2014).

42. Szklarczyk, D. et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607–D613 (2019).

43. Lehnert, S., Götz, C., Kartarius, S., Schäfer, B. & Montenarh, M. Protein kinase CK2 interacts with the splicing factor hPrp3p. Oncogene 27, 2390– 2400 (2008).

44. Litchfield, D. W. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem. J 369, 1–15 (2003).

45. Whittard, J. D. & Akiyama, S. K. Positive regulation of cell-cell and cell- substrate adhesion by protein kinase A. J. Cell Sci. 114, 3265–3272 (2001).

46. Buljan, M. et al. Kinase Interaction Network Expands Functional and Disease Roles of Human Kinases. Mol. Cell 79, 504–520.e9 (2020).

47. Siddiqui-Jain, A. et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 70, 10288–10298 (2010).

48. Seamon, K. B., Daly, J. W., Metzger, H., de Souza, N. J. & Reden, J. Structure-activity relationships for activation of adenylate cyclase by the diterpene forskolin and its derivatives. J. Med. Chem. 26, 436–439 (1983).

49. Sugiyama, N. et al. Phosphopeptide enrichment by aliphatic hydroxy acid- modified metal oxide chromatography for nano-LC-MS/MS in proteomics applications. Mol. Cell. Proteomics 6, 1103–1109 (2007).

50. Crooks, G. E., Hon, G., Chandonia, J.-M. & Brenner, S. E. WebLogo: a sequence logo generator. Genome Res. 14, 1188–1190 (2004).

51. Wasserman, W. W. & Sandelin, A. Applied bioinformatics for the identification of regulatory elements. Nat. Rev. Genet. 5, 276–287 (2004).

52. Geiger, T., Wehner, A., Schaab, C., Cox, J. & Mann, M. Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins. Mol. Cell. Proteomics 11, M111.014050 (2012).

53. Trembley, J. H. et al. Activation of pre-mRNA splicing by human RNPS1 is regulated by CK2 phosphorylation. Mol. Cell. Biol. 25, 1446–1457 (2005).

54. Wagih, O., Reimand, J. & Bader, G. D. MIMP: predicting the impact of mutations on kinase-substrate phosphorylation. Nat. Methods 12, 531–533 (2015).

55. Reimand, J., Wagih, O. & Bader, G. D. The mutational landscape of phosphorylation signaling in cancer. Sci. Rep. 3, 2651 (2013).

56. Caretta, A. & Mucignat-Caretta, C. Protein kinase a in cancer. Cancers 3, 913–926 (2011).

57. Chua, M. M. J. et al. CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target. Pharmaceuticals 10, (2017).

58. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, l1 (2013).

59. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401– 404 (2012).

60. Oughtred, R. et al. The BioGRID database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactions. Protein Sci. 30, 187–200 (2021).

61. Samavarchi-Tehrani, P., Samson, R. & Gingras, A.-C. Proximity Dependent Biotinylation: Key Enzymes and Adaptation to Proteomics Approaches. Mol. Cell. Proteomics 19, 757–773 (2020).

62. Klaeger, S. et al. The target landscape of clinical kinase drugs. Science 358, (2017).

63. Schmitt, J. M. & Stork, P. J. S. PKA phosphorylation of Src mediates cAMP’s inhibition of cell growth via Rap1. Mol. Cell 9, 85–94 (2002).

64. Julien, S. G., Dubé, N., Hardy, S. & Tremblay, M. L. Inside the human cancer tyrosine phosphatome. Nat. Rev. Cancer 11, 35–49 (2011).

65. Saraon, P. et al. Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches. Oncogene 40, 4079–4093 (2021).

66. Alonso, A. & Pulido, R. The extended human PTPome: a growing tyrosine phosphatase family. FEBS J. 283, 2197–2201 (2016).

67. Lyons, S. P. et al. A Quantitative Chemical Proteomic Strategy for Profiling Phosphoprotein Phosphatases from Yeast to Humans. Mol. Cell. Proteomics 17, 2448–2461 (2018).

68. Karisch, R. et al. Global proteomic assessment of the classical protein- tyrosine phosphatome and ‘Redoxome’. Cell 146, 826–840 (2011).

69. Liu, S. et al. Aryl vinyl sulfonates and sulfones as active site-directed and mechanism-based probes for protein tyrosine phosphatases. J. Am. Chem. Soc. 130, 8251–8260 (2008).

70. Kumar, S. et al. Activity-based probes for protein tyrosine phosphatases. Proc. Natl. Acad. Sci. U. S. A. 101, 7943–7948 (2004).

71. Kalesh, K. A. et al. Peptide-based activity-based probes (ABPs) for target- specific profiling of protein tyrosine phosphatases (PTPs). Chem. Commun. 46, 589–591 (2010).

72. Casey, G. R. & Stains, C. I. Interrogating Protein Phosphatases with Chemical Activity Probes. Chemistry 24, 7810–7824 (2018).

73. Chen, L. et al. Why is phosphonodifluoromethyl phenylalanine a more potent inhibitory moiety than phosphonomethyl phenylalanine toward protein- tyrosine phosphatases? Biochem. Biophys. Res. Commun. 216, 976–984 (1995).

74. Meyer, C., Hoeger, B., Chatterjee, J. & Köhn, M. Azide-alkyne cycloaddition- mediated cyclization of phosphonopeptides and their evaluation as PTP1B binders and enrichment tools. Bioorg. Med. Chem. 23, 2848–2853 (2015).

75. Meyer, C. et al. Development of Accessible Peptidic Tool Compounds To Study the Phosphatase PTP1B in Intact Cells. ACS Chemical Biology vol. 9 769–776 (2014).

76. Tsumagari, K., Niinae, T., Otaka, A. & Ishihama, Y. Peptide probes containing a non-hydrolyzable phosphotyrosine-mimetic residue for enrichment of protein tyrosine phosphatases. Proteomics e2100144 (2021).

77. Palma, A. et al. Both Intrinsic Substrate Preference and Network Context Contribute to Substrate Selection of Classical Tyrosine Phosphatases. J. Biol. Chem. 292, 4942–4952 (2017).

78. Sharma, K. et al. Proteomics strategy for quantitative protein interaction profiling in cell extracts. Nat. Methods 6, 741–744 (2009).

79. Zhang, Y. L. et al. Thermodynamic study of ligand binding to protein- tyrosine phosphatase 1B and its substrate-trapping mutants. J. Biol. Chem. 275, 34205–34212 (2000).

80. Damle, N. P. & Köhn, M. The human DEPhOsphorylation Database DEPOD: 2019 update. Database 2019, (2019).

81. Guo, Y. et al. Tim50, a component of the mitochondrial translocator, regulates mitochondrial integrity and cell death. J. Biol. Chem. 279, 24813– 24825 (2004).

82. Burke, T. R., Jr et al. Nonhydrolyzable phosphotyrosyl mimetics for the preparation of phosphatase-resistant SH2 domain inhibitors. Biochemistry 33, 6490–6494 (1994).

83. Schulze, W. X., Deng, L. & Mann, M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol. Syst. Biol. 1, 2005.0008 (2005).

84. Tinti, M. et al. The SH2 domain interaction landscape. Cell Rep. 3, 1293– 1305 (2013).

85. Lundby, A. et al. Oncogenic Mutations Rewire Signaling Pathways by Switching Protein Recruitment to Phosphotyrosine Sites. Cell 179, 543– 560.e26 (2019).

86. Hanke, S. & Mann, M. The phosphotyrosine interactome of the insulin receptor family and its substrates IRS-1 and IRS-2. Mol. Cell. Proteomics 8, 519–534 (2009).

87. Benes, C. H. et al. The C2 domain of PKCdelta is a phosphotyrosine binding domain. Cell 121, 271–280 (2005).

88. Christofk, H. R., Vander Heiden, M. G., Wu, N., Asara, J. M. & Cantley, L. C. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452, 181–186 (2008).

89. Huang, C.-F. & Mrksich, M. Profiling Protein Tyrosine Phosphatase Specificity with Self-Assembled Monolayers for Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry and Peptide Arrays. ACS Comb. Sci. 21, 760–769 (2019).

90. Selner, N. G. et al. Diverse levels of sequence selectivity and catalytic efficiency of protein-tyrosine phosphatases. Biochemistry 53, 397–412 (2014).

91. Irving, E. & Stoker, A. W. Vanadium Compounds as PTP Inhibitors. Molecules 22, (2017).

92. Ostman, A., Frijhoff, J., Sandin, A. & Böhmer, F.-D. Regulation of protein tyrosine phosphatases by reversible oxidation. J. Biochem. 150, 345–356 (2011).

93. Londhe, A. D. et al. Regulation of PTP1B activation through disruption of redox-complex formation. Nat. Chem. Biol. 16, 122–125 (2020).

94. Lee, S. R., Kwon, K. S., Kim, S. R. & Rhee, S. G. Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. J. Biol. Chem. 273, 15366–15372 (1998).

95. Kumar, S. et al. Global analysis of protein tyrosine phosphatase activity with ultra-sensitive fluorescent probes. J. Proteome Res. 5, 1898–1905 (2006).

96. Olsen, J. V. et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127, 635–648 (2006).

97. Talha, S. & Harel, L. Early effect of growth factors (EGF + insulin) upon ATP turnover in 3T3 cells. Exp. Cell Res. 149, 471–481 (1983).

98. Emmerson, K. & Roehrig, K. Epidermal growth factor (EGF) stimulation of ATP citrate lyase activity in isolated rat hepatocytes is age dependent. Comp. Biochem. Physiol. B 103, 663–667 (1992).

99. Makukhin, N. & Ciulli, A. Recent advances in synthetic and medicinal chemistry of phosphotyrosine and phosphonate-based phosphotyrosine analogues. RSC Med Chem 12, 8–23 (2020).

100. Lemmon, M. A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117–1134 (2010).

101. Barr, A. J. et al. Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 136, 352–363 (2009).

102. Coles, C. H. et al. Proteoglycan-specific molecular switch for RPTPσ clustering and neuronal extension. Science 332, 484–488 (2011).

103. Rappsilber, J., Mann, M. & Ishihama, Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat. Protoc. 2, 1896–1906 (2007).

104. Masuda, T., Tomita, M. & Ishihama, Y. Phase transfer surfactant-aided trypsin digestion for membrane proteome analysis. J. Proteome Res. 7, 731– 740 (2008).

105. McAlister, G. C. et al. MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes. Anal. Chem. 86, 7150–7158 (2014).

106. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372 (2008).

107. Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731–740 (2016).

108. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57 (2009).

109. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1–13 (2009).